Daytrana ADHD Patch Response Submitted To FDA – Noven
This article was originally published in The Pink Sheet Daily
Executive Summary
The company says it has submitted a response to FDA’s “approvable letter” for the methylphenidate transdermal system.
You may also be interested in...
Sparlon Shows 31 Cases Of Suicidality, Aggression or Psychosis In ADHD Database
Incidence of events with Sparlon is higher than for placebo but exposure in patients is also greater, FDA summary of clinical adverse events states.
Sparlon Shows 31 Cases Of Suicidality, Aggression or Psychosis In ADHD Database
Incidence of events with Sparlon is higher than for placebo but exposure in patients is also greater, FDA summary of clinical adverse events states.
Shire/Noven Daytrana "Approvable" Pending Data Clarification
FDA letter for the ADHD patch also requests additional information on post-marketing surveillance and post-marketing studies, the companies say.